Vibe Rounds - EBM Query Results
Rx: questions, not answers
clinical reasoning aid · not for patient care
Educational use only. All AI-generated queries, PICO breakdowns, and search strings below require independent clinical verification before being acted upon. This is a draft list of questions and search strategies — not answers, not a diagnosis, and not a treatment recommendation.
Therapy
Diagnosis
Prognosis
Harm
Cost-effectiveness
Guideline
1
Structured EBM Queries
7/26/2026, 11:18:29 PM
1. Therapy Query
Best Study Design: Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials (RCTs), or a Large Multicenter RCT
Draft PICO(T):
- P: Adults with heart failure with reduced ejection fraction (LVEF ≤ 40%) and concomitant type 2 diabetes mellitus
- I: Addition of an SGLT2 inhibitor (e.g., dapagliflozin or empagliflozin) to standard medical therapy
- C: Placebo or standard therapy alone without an SGLT2 inhibitor
- O: Reduction in heart failure hospitalizations, improvement in functional status/exercise tolerance, and all-cause/cardiovascular mortality
- T: Medium to long-term (≥6 to 24 months)
Draft PubMed-Ready Search String:
("Sodium-Glucose Transporter 2 Inhibitors"[Mesh] OR "SGLT2 inhibitors" OR "dapagliflozin" OR "empagliflozin") AND ("Heart Failure"[Mesh] OR "HFrEF" OR "heart failure with reduced ejection fraction") AND ("Diabetes Mellitus, Type 2"[Mesh]) AND ("Patient Hospitalization"[Mesh] OR "hospitalization" OR "Quality of Life"[Mesh] OR "exercise tolerance" OR "dyspnea") AND (randomized controlled trial[pt] OR systematic review[pt])
Appraisal Checklist:
CASP RCT Checklist
PRISMA (if systematic review)
2. Diagnosis Query
Best Study Design: Prospective Cross-Sectional Diagnostic Accuracy Study with consecutive sampling and blinded reference standard comparison
Draft PICO(T):
- P: Adults with type 2 diabetes presenting with exertional dyspnea and lower extremity edema in an outpatient setting
- I (Index Test): Serum B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) level
- C (Reference Standard): Comprehensive cardiology evaluation including echocardiogram and clinical diagnostic criteria for decompensated heart failure
- O: Diagnostic accuracy metrics (sensitivity, specificity, PPV/NPV, likelihood ratios, AUC) for identifying active congestive heart failure
- T: Point-of-care / initial clinical evaluation
Draft PubMed-Ready Search String:
("Natriuretic Peptide, Brain"[Mesh] OR "NT-proBNP" OR "BNP") AND ("Heart Failure"[Mesh] OR "dyspnea") AND ("Diabetes Mellitus, Type 2"[Mesh]) AND ("Sensitivity and Specificity"[Mesh] OR "Predictive Value of Tests"[Mesh] OR "ROC Curve")
Appraisal Checklist:
QUADAS-2
CASP Diagnostic Test Checklist
3. Prognosis Query
Best Study Design: Prospective Longitudinal Cohort Study
Draft PICO(T):
- P: Adults with type 2 diabetes and newly diagnosed heart failure with reduced ejection fraction (LVEF ≤ 40%) receiving incomplete guideline-directed medical therapy
- I/E: Baseline LVEF, functional class, and comorbidity burden (diabetes, hypertension)
- C: N/A (or comparison across baseline risk-stratification tiers / ejection-fraction categories)
- O: Incidence of heart failure hospitalization, functional decline, and 1-to-5-year all-cause mortality
- T: 1 to 5 years follow-up
Draft PubMed-Ready Search String:
("Heart Failure"[Mesh] OR "HFrEF") AND ("Diabetes Mellitus, Type 2"[Mesh]) AND ("Prognosis"[Mesh] OR "Prognostic Factors" OR "Mortality"[Mesh] OR "Hospitalization"[Mesh]) AND ("Cohort Studies"[Mesh] OR "prognostic study")
Appraisal Checklist:
CASP Cohort Study Checklist
QUIPS
4. Harm Query
Best Study Design: Systematic Review of RCTs or Prospective Cohort Study / Case-Control Study (for rare adverse events)
Draft PICO(T):
- P: Older adult women (age ≥ 60) with type 2 diabetes and heart failure
- I/Exposure: Initiation of SGLT2 inhibitor therapy
- C: Non-exposure / placebo / alternative antihyperglycemic regimen
- O: Incidence of severe adverse events (e.g., euglycemic diabetic ketoacidosis, mycotic genital infections, urinary tract infections, volume depletion/hypotension, acute kidney injury)
- T: Short to long-term (weeks to 2 years)
Search string generation was cut off in the original run before completing this query, and no Cost-effectiveness or Guideline-check query threads were produced. Re-run generation to fill these in.
2
Stress-Test Queries
7/26/2026, 11:19:05 PM
Therapy Thread
What is the strongest argument that the mortality and hospitalization benefits of adding SGLT2 inhibitors to standard therapy in patients with HFrEF and type 2 diabetes are wrong or overstated, given the evidence?
Diagnosis Thread
What is the strongest argument that the diagnostic accuracy of BNP/NT-proBNP for identifying active heart failure in patients with type 2 diabetes is wrong or overstated, given the confounding effects of obesity and diabetic nephropathy on biomarker levels?
Prognosis Thread
What is the strongest argument that baseline comorbidity burden and incomplete GDMT are overstated as the primary independent prognostic drivers of 1-to-5-year mortality in T2D patients with newly diagnosed HFrEF, given the evidence?
Harm Thread
What is the strongest argument that the clinical risk of severe adverse events (such as euglycemic DKA, volume depletion, or AKI) from SGLT2 inhibitors in older adult women with heart failure and T2D is wrong or overstated, given the evidence?
3
Patient Priority Restated
7/26/2026, 11:19:22 PM
In her own words
"Staying out of the hospital and being able to walk my dog without stopping to catch my breath."
"To be used on personal responsibility and only for learning. Not to be used for clinical purpose."
The LLM drafts. You verify every number and citation against the source.